{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:50:33Z","timestamp":1790974233947,"version":"4.1.0"},"reference-count":81,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T00:00:00Z","timestamp":1652572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Science ICT &amp; Future Planning","award":["2017R1A2B2003575"],"award-info":[{"award-number":["2017R1A2B2003575"]}]},{"name":"Ministry of Science ICT &amp; Future Planning","award":["NRF-2020R1A2C1006398"],"award-info":[{"award-number":["NRF-2020R1A2C1006398"]}]},{"name":"Ministry of Science ICT &amp; Future Planning","award":["2020R1C1C1012288"],"award-info":[{"award-number":["2020R1C1C1012288"]}]},{"name":"Ministry of Science ICT &amp; Future Planning","award":["IITP-2022-2020-0-01819"],"award-info":[{"award-number":["IITP-2022-2020-0-01819"]}]},{"name":"Ministry of Science ICT &amp; Future Planning","award":["HI17C0387"],"award-info":[{"award-number":["HI17C0387"]}]},{"name":"Ministry of Science and ICT","award":["2017R1A2B2003575"],"award-info":[{"award-number":["2017R1A2B2003575"]}]},{"name":"Ministry of Science and ICT","award":["NRF-2020R1A2C1006398"],"award-info":[{"award-number":["NRF-2020R1A2C1006398"]}]},{"name":"Ministry of Science and ICT","award":["2020R1C1C1012288"],"award-info":[{"award-number":["2020R1C1C1012288"]}]},{"name":"Ministry of Science and ICT","award":["IITP-2022-2020-0-01819"],"award-info":[{"award-number":["IITP-2022-2020-0-01819"]}]},{"name":"Ministry of Science and ICT","award":["HI17C0387"],"award-info":[{"award-number":["HI17C0387"]}]},{"name":"ICT Creative Consilience program","award":["2017R1A2B2003575"],"award-info":[{"award-number":["2017R1A2B2003575"]}]},{"name":"ICT Creative Consilience program","award":["NRF-2020R1A2C1006398"],"award-info":[{"award-number":["NRF-2020R1A2C1006398"]}]},{"name":"ICT Creative Consilience program","award":["2020R1C1C1012288"],"award-info":[{"award-number":["2020R1C1C1012288"]}]},{"name":"ICT Creative Consilience program","award":["IITP-2022-2020-0-01819"],"award-info":[{"award-number":["IITP-2022-2020-0-01819"]}]},{"name":"ICT Creative Consilience program","award":["HI17C0387"],"award-info":[{"award-number":["HI17C0387"]}]},{"DOI":"10.13039\/501100003710","name":"IITP, the Korea Health Technology R&amp;D Project","doi-asserted-by":"publisher","award":["2017R1A2B2003575"],"award-info":[{"award-number":["2017R1A2B2003575"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"IITP, the Korea Health Technology R&amp;D Project","doi-asserted-by":"publisher","award":["NRF-2020R1A2C1006398"],"award-info":[{"award-number":["NRF-2020R1A2C1006398"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"IITP, the Korea Health Technology R&amp;D Project","doi-asserted-by":"publisher","award":["2020R1C1C1012288"],"award-info":[{"award-number":["2020R1C1C1012288"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"IITP, the Korea Health Technology R&amp;D Project","doi-asserted-by":"publisher","award":["IITP-2022-2020-0-01819"],"award-info":[{"award-number":["IITP-2022-2020-0-01819"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"IITP, the Korea Health Technology R&amp;D Project","doi-asserted-by":"publisher","award":["HI17C0387"],"award-info":[{"award-number":["HI17C0387"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"name":"KHIDI and the Ministry of Health and Welfare","award":["2017R1A2B2003575"],"award-info":[{"award-number":["2017R1A2B2003575"]}]},{"name":"KHIDI and the Ministry of Health and Welfare","award":["NRF-2020R1A2C1006398"],"award-info":[{"award-number":["NRF-2020R1A2C1006398"]}]},{"name":"KHIDI and the Ministry of Health and Welfare","award":["2020R1C1C1012288"],"award-info":[{"award-number":["2020R1C1C1012288"]}]},{"name":"KHIDI and the Ministry of Health and Welfare","award":["IITP-2022-2020-0-01819"],"award-info":[{"award-number":["IITP-2022-2020-0-01819"]}]},{"name":"KHIDI and the Ministry of Health and Welfare","award":["HI17C0387"],"award-info":[{"award-number":["HI17C0387"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chronic rhinosinusitis is a chronic inflammatory disease of the upper airways, for which treatment options include medical or surgical therapy. However, there are limitations to conservative treatment strategies, such as the relapse of nasal polyps. In this review, we discuss the rising role of biomolecular mechanisms associated with various biologics that have been approved or are undergoing clinical trials to treat chronic rhinosinusitis. We also highlight the potential molecular therapeutic targets for managing and treating chronic rhinosinusitis.<\/jats:p>","DOI":"10.3390\/ijms23105523","type":"journal-article","created":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T09:48:22Z","timestamp":1652608102000},"page":"5523","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Therapeutic Strategies of Biologics in Chronic Rhinosinusitis: Current Options and Future Targets"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1491-9889","authenticated-orcid":false,"given":"Junhu","family":"Tai","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology-Head & Neck Surgery, College of Medicine, Korea University, Seoul 02841, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1359-6248","authenticated-orcid":false,"given":"Munsoo","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology-Head & Neck Surgery, College of Medicine, Korea University, Seoul 02841, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Hoon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology-Head & Neck Surgery, College of Medicine, Korea University, Seoul 02841, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lee, K., Tai, J., Lee, S.H., and Kim, T.H. (2021). Advances in the Knowledge of the Underlying Airway Remodeling Mechanisms in Chronic Rhinosinusitis Based on the Endotypes: A Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020910"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2500\/ajra.2011.25.3630","article-title":"Prevalence and risk factors of chronic rhinosinusitis in Korea","volume":"25","author":"Kim","year":"2011","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/all.12577","article-title":"Epidemiology of chronic rhinosinusitis: Results from a cross-sectional survey in seven Chinese cities","volume":"70","author":"Shi","year":"2015","journal-title":"Allergy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1177\/0194599818774006","article-title":"Prevalence of Potential Adult Chronic Rhinosinusitis Symptoms in the United States","volume":"159","author":"Bhattacharyya","year":"2018","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1398-9995.2011.02646.x","article-title":"Chronic rhinosinusitis in Europe\u2014An underestimated disease. A GA2LEN study","volume":"66","author":"Hastan","year":"2011","journal-title":"Allergy"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/lary.27852","article-title":"Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps","volume":"129","author":"Bhattacharyya","year":"2019","journal-title":"Laryngoscope"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/ACI.0000000000000329","article-title":"Medical therapy, refractory chronic rhinosinusitis, and productivity costs","volume":"17","author":"Smith","year":"2017","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.anai.2019.12.001","article-title":"Biologics in chronic rhinosinusitis with nasal polyposis","volume":"124","author":"Laidlaw","year":"2020","journal-title":"Ann. Allergy Asthma Immunol. Off. Publ. Am. Coll. Allergy Asthma Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaip.2015.01.013","article-title":"Biologic therapies targeting eosinophils: Current status and future prospects","volume":"3","author":"Legrand","year":"2015","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/0145561320964653","article-title":"The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps","volume":"100","author":"Patel","year":"2021","journal-title":"Ear Nose Throat J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jaip.2017.04.024","article-title":"Biotherapeutics in Chronic Rhinosinusitis with and without Nasal Polyps","volume":"5","author":"Bachert","year":"2017","journal-title":"J. Allergy Clin. Immunol.. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.iac.2019.12.006","article-title":"The Role of Biologics in the Treatment of Nasal Polyps","volume":"40","author":"Franzese","year":"2020","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40265-020-01298-9","article-title":"Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.alit.2017.04.006","article-title":"T follicular helper and T(H)2 cells in allergic responses","volume":"66","author":"Kubo","year":"2017","journal-title":"Allergol. Int. Off. J. Jpn. Soc. Allergol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Siddiqui, S., Johansson, K., Joo, A., Bonser, L.R., Koh, K.D., Le Tonqueze, O., Bolourchi, S., Bautista, R.A., Zlock, L., and Roth, T.L. (2021). Epithelial miR-141 regulates IL-13-induced airway mucus production. JCI Insight, 6.","DOI":"10.1172\/jci.insight.139019"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.iac.2020.06.001","article-title":"Biologics for the Treatment of Allergic Rhinitis, Chronic Rhinosinusitis, and Nasal Polyposis","volume":"40","author":"Eschenbacher","year":"2020","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14639\/0392-100X-N1614","article-title":"Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: A change management approach. Consensus of the Joint Committee of Italian Society of Otorhinolaryngology on biologics in rhinology","volume":"42","author":"Bellocchi","year":"2022","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.anai.2021.01.012","article-title":"Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma","volume":"126","author":"Laidlaw","year":"2021","journal-title":"Ann. Allergy Asthma Immunol. Off. Publ. Am. Coll. Allergy Asthma Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjd.18179","article-title":"Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: Daily practice data","volume":"182","author":"Bosma","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13643-015-0157-5","article-title":"Anti-IgE monoclonal antibody therapy for the treatment of chronic rhinosinusitis: A systematic review","volume":"4","author":"Hong","year":"2015","journal-title":"Syst. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jama.2015.7544","article-title":"Medical Therapies for Adult Chronic Sinusitis: A Systematic Review","volume":"314","author":"Rudmik","year":"2015","journal-title":"JAMA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1038\/srep11581","article-title":"Structural and Physical Basis for Anti-IgE Therapy","volume":"5","author":"Wright","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.anai.2019.10.016","article-title":"Asthma biologics: Comparing trial designs, patient cohorts and study results","volume":"124","author":"Doroudchi","year":"2020","journal-title":"Ann. Allergy Asthma Immunol. Off. Publ. Am. Coll. Allergy Asthma Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4193\/Rhin17.139","article-title":"Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together\u2014A real life study","volume":"56","author":"Bidder","year":"2018","journal-title":"Rhinology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1177\/1945892420972326","article-title":"Effects of Omalizumab Treatment in Patients With Recalcitrant Nasal Polyposis and Mild Asthma: A Multicenter Retrospective Study","volume":"35","author":"Miguel","year":"2021","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4193\/Rhin16.314","article-title":"The effect of systemic treatments on periostin expression reflects their interference with the eosinophilic inflammation in chronic rhinosinusitis with nasal polyps","volume":"55","author":"Derycke","year":"2017","journal-title":"Rhinology"},{"key":"ref_33","first-page":"341","article-title":"Omalizumab (Xolair) for treatment of asthma","volume":"71","author":"Davydov","year":"2005","journal-title":"Am. Fam. Physician"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.iac.2017.06.001","article-title":"Subcutaneous Injectable Drugs Hypersensitivity and Desensitization: Insulin and Monoclonal Antibodies","volume":"37","author":"Bavbek","year":"2017","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMra0804579","article-title":"Asthma","volume":"360","author":"Fanta","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jaci.2022.02.016","article-title":"Mechanisms and pathogenesis of chronic rhinosinusitis","volume":"149","author":"Kato","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cyto.2015.02.005","article-title":"The \u03b2c receptor family - Structural insights and their functional implications","volume":"74","author":"Broughton","year":"2015","journal-title":"Cytokine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet. Respir. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/1744666X.2020.1724089","article-title":"Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases","volume":"16","author":"Jackson","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.anai.2016.10.028","article-title":"Assessing the value of mepolizumab for severe eosinophilic asthma: A cost-effectiveness analysis","volume":"118","author":"Whittington","year":"2017","journal-title":"Ann. Allergy Asthma Immunol. Off. Publ. Am. Coll. Allergy Asthma Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/17425255.2018.1421170","article-title":"Pharmacokinetic\/pharmacodynamic profile of reslizumab in asthma","volume":"14","author":"Matera","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40265-016-0583-2","article-title":"Reslizumab: First Global Approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12016-019-08734-z","article-title":"Therapeutic Antibodies for Nasal Polyposis Treatment: Where Are We Headed?","volume":"59","author":"Agarwal","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1517\/14712598.2012.642359","article-title":"Benralizumab\u2014A humanized mAb to IL-5R\u03b1 with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma","volume":"12","author":"Ghazi","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/17476348.2020.1739526","article-title":"Benralizumab: An updated treatment of eosinophilic asthma","volume":"14","author":"Cushen","year":"2020","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.jaip.2020.01.031","article-title":"Current and Future Treatments of Rhinitis and Sinusitis","volume":"8","author":"Patel","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1111\/all.14526","article-title":"Role of IL-25, IL-33, and TSLP in triggering united airway diseases toward type 2 inflammation","volume":"75","author":"Hong","year":"2020","journal-title":"Allergy"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jaci.2015.01.003","article-title":"IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis","volume":"135","author":"Shin","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40521-021-00282-2","article-title":"Biologics in Treatment for Chronic Rhinosinusitis with Comorbid Asthma","volume":"8","author":"Xu","year":"2021","journal-title":"Curr. Treat. Options Allergy"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in Adults with Uncontrolled Asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti\u2013IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2004.09.029","article-title":"Rhinosinusitis: Establishing definitions for clinical research and patient care","volume":"114","author":"Meltzer","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2016.05.041","article-title":"Diversity of T(H) cytokine profiles in patients with chronic rhinosinusitis: A multicenter study in Europe, Asia, and Oceania","volume":"138","author":"Wang","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.jaip.2019.05.009","article-title":"Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis","volume":"7","author":"Stevens","year":"2019","journal-title":"J. Allergy Clin. Immunol.. Pract."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/ecco-jcc\/jjaa260","article-title":"Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review","volume":"15","author":"Guillo","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1474-4422(10)70033-8","article-title":"Daclizumab in active relapsing multiple sclerosis (CHOICE study): A phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta","volume":"9","author":"Wynn","year":"2010","journal-title":"Lancet. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ibd.21038","article-title":"Fontolizumab in moderate to severe Crohn\u2019s disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study","volume":"16","author":"Reinisch","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","article-title":"Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes","volume":"378","author":"Gattorno","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e000731","DOI":"10.1136\/rmdopen-2018-000731","article-title":"Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study","volume":"4","author":"Thorne","year":"2018","journal-title":"RMD Open"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/14712598.2020.1729736","article-title":"Ixekizumab for the treatment of psoriasis: Up-to-date","volume":"20","author":"Craig","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial","volume":"78","author":"Brunner","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1111\/all.14620","article-title":"Adult-onset eosinophilic airway diseases","volume":"75","author":"Asano","year":"2020","journal-title":"Allergy"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.anai.2018.10.014","article-title":"Pathophysiologic mechanisms of chronic rhinosinusitis and their roles in emerging disease endotypes","volume":"122","author":"Cao","year":"2019","journal-title":"Ann. Allergy Asthma Immunol. Off. Publ. Am. Coll. Allergy Asthma Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.4049\/jimmunol.165.3.1548","article-title":"CXCR3 expression and activation of eosinophils: Role of IFN-gamma-inducible protein-10 and monokine induced by IFN-gamma","volume":"165","author":"Jinquan","year":"2000","journal-title":"J. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"R74","DOI":"10.1186\/ar616","article-title":"A novel mechanism for the regulation of IFN-gamma inducible protein-10 expression in rheumatoid arthritis","volume":"5","author":"Hanaoka","year":"2003","journal-title":"Arthritis Res. Ther."},{"key":"ref_72","first-page":"22","article-title":"High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis","volume":"27","author":"Antonelli","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.autrev.2012.10.001","article-title":"The interaction between CXCL10 and cytokines in chronic inflammatory arthritis","volume":"12","author":"Lee","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41385-019-0149-1","article-title":"The IFN-\u03b3-p38, ERK kinase axis exacerbates neutrophilic chronic rhinosinusitis by inducing the epithelial-to-mesenchymal transition","volume":"12","author":"Lee","year":"2019","journal-title":"Mucosal Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2332\/allergolint.13-OA-0572","article-title":"Increased CXCL10 expression in nasal fibroblasts from patients with refractory chronic rhinosinusitis and asthma","volume":"62","author":"Yoshikawa","year":"2013","journal-title":"Allergol. Int. Off. J. Jpn. Soc. Allergol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12016-015-8498-3","article-title":"OX40, OX40L and Autoimmunity: A Comprehensive Review","volume":"50","author":"Webb","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Furue, M., and Furue, M. (2021). OX40L-OX40 Signaling in Atopic Dermatitis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10122578"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","article-title":"GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis","volume":"144","author":"Pavel","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.arcmed.2019.11.003","article-title":"Effect of Blocking the OX40\/OX40L Signaling Pathway by siRNA Interference on Animal Experimental Study of Allergic Rhinitis","volume":"50","author":"Liang","year":"2019","journal-title":"Arch. Med. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/MAJ.0b013e3181f20489","article-title":"Role of thymic stromal lymphopoietin in the pathogenesis of nasal polyposis","volume":"341","author":"Liu","year":"2011","journal-title":"Am. J. Med. Sci."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/10\/5523\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:11:00Z","timestamp":1760137860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/10\/5523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,15]]},"references-count":81,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["ijms23105523"],"URL":"https:\/\/doi.org\/10.3390\/ijms23105523","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,15]]}}}